Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: West Haven, Connecticut Clear all
Active, not recruiting Phase 3 Interventional

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389
View directory record Official record
Conditions
Myelofibrosis
Interventions
Selinexor, Placebo, Ruxolitinib
Drug · Other
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional Results available

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

NCT00991029
View directory record Official record
Conditions
Ischemic Attack, Transient
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
147
States / cities
Chandler, Arizona • Tucson, Arizona • Carmichael, California + 95 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Intensive Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)

NCT01120067
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Intensive Treatment, Treatment as Usual
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feedback and Outcomes for Clinically Useful Student Services (FOCUSS)

NCT05039671
View directory record Official record
Conditions
School-based Mental Health Treatment Services
Interventions
Measurement-based care (MBC)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Stamford, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 17, 2026, 5:24 AM EDT
Recruiting Not applicable Interventional

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

NCT04743765
View directory record Official record
Conditions
Hip Fractures, Myocardial Injury
Interventions
Accelerated medical clearance and surgery
Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Chandler, Arizona • Davis, California • Irvine, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Active, not recruiting Phase 3 Interventional

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT02488967
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1286
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 815 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Recruiting Not applicable Interventional

Assessing the Efficacy of an Acceptance-Based Digital Intervention for Veterans With Chronic Pain

NCT06058624
View directory record Official record
Conditions
Chronic Pain
Interventions
Veteran ACT for Chronic Pain (VACT-CP), Online Pain School
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
West Haven, Connecticut • Bedford, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
374
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Phase 1Phase 2 Interventional

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Not applicable Interventional

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

NCT00002000
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Mobile, Alabama • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02965378
View directory record Official record
Conditions
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1083
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813
View directory record Official record
Conditions
Heart Failure
Interventions
Torsemide, Furosemide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

Psilocybin for the Treatment of Migraine Headache

NCT03341689
View directory record Official record
Conditions
Migraine Headache
Interventions
High Dose Psilocybin, Low Dose Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 17, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1226
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
280
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Dublin, California + 223 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

NCT05076149
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 17, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional Results available

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

NCT02927249
View directory record Official record
Conditions
Node Positive HER2 Negative Breast Cancer
Interventions
Placebo, Aspirin
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1426
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT05976763
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration
Drug · Biological · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
60 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
238
States / cities
Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Standard Adjuvant Endocrine Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
162
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)

NCT03540771
View directory record Official record
Conditions
End Stage Liver Disease, Decompensated Cirrhosis of Liver
Interventions
Palliative Care
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 120 Years
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 5:24 AM EDT
Active, not recruiting Phase 3 Interventional

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04095364
View directory record Official record
Conditions
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
883
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

NCT03833167
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
Mobile, Alabama • Duarte, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692
View directory record Official record
Conditions
PTSD, Posttraumatic Stress Disorder
Interventions
Ketamine, Placebo/Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 17, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Results available

An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment

NCT05051644
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
Steps 2 Change (S2C), Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 5:24 AM EDT